Scorpion Therapeutics develops precision oncology treatments aimed at targeting specific cancer drivers. Their approach involves creating drugs that interact with validated cancer targets, enhancing their selectivity and safety to improve treatment efficacy. Unlike many competitors, Scorpion Therapeutics focuses on forming partnerships with larger pharmaceutical companies for the distribution of their drugs, allowing them to concentrate on research and development. Their goal is to provide effective cancer treatments that can make a significant impact on patients' lives, leveraging a team of experts in various scientific fields to achieve this.

Abingworth

Vida Ventures

Partners HealthCare

Atlas Venture

Omega Funds

EcoR1 Capital

Tavistock Group

Invus

Logos Capital

Janus Henderson Investors

Casdin Capital

Woodline Partners

Nextech Invest

Boxer Capital

OrbiMed

Wellington Management

Lightspeed Venture Partners

Frazier Life Sciences

Willett Advisors

Surveyor Capital

Fidelity Investments

Biotechnology

Healthcare

Scorpion Therapeutics

In conjunction with the funding, Lightspeed Venture partner Shelley Chu will become an investor board member and Frazier Life Sciences managing partner Albert Cha will join the board of Scorpion as an observer.

Scorpion Therapeutics secures $150m for oncology pipeline

Scorpion Therapeutics, a Boston, MA-based clinical-stage oncology company, raised $150M in Series C funding

Scorpion Therapeutics Raises $150M in Series C Financing

Streit joined Scorpion in 2022 from Sanofi, where he had most recently served as vice president and senior project head.

Scorpion's CEO Axel Hoos, CMO bite the dust as oncology biotech brings in new leadership

Scorpion Therapeutics appoints Adam Friedman, M.D., Ph.D., as Chief Executive Officer and expands Leadership Team.

Scorpion Therapeutics Appoints Adam Friedman, M.D., Ph.D., as Chief Executive Officer and Expands Leadership Team

Scorpion Therapeutics appoints precision medicine leader Jeff Albers as strategic advisor.

Scorpion Therapeutics Appoints Precision Medicine Leader Jeff Albers as Strategic Advisor

French pharma-cosmetic company Pierre Fabre has acquired the rights from Scorpion Therapeutics for two epidermal growth factor receptor (EGFR) inhibitors in Europe and China.

Pierre Fabre in $618m deal with Scorpion

BOSTON--(BUSINESS WIRE)--Scorpion Therapeutics, Inc. (“Scorpion”), a pioneering oncology company redefining the frontier of precision medicine through its Precision Oncology 2.0 strategy, today announced preclinical data demonstrating that STX-478, the Company's highly differentiated, allosteric and central nervous-system (“CNS”) penetrant inhibitor of mutant phosphoinositide-3-kinase alpha (“PI3Kα”), has a potentially best-in-class product profile, with the ability to improve outcomes in patients harboring tumors with prevalent PI3Kα kinase or helical domain mutations. The data is being presented for the first time today in a poster session at the San Antonio Breast Cancer Symposium (“SABCS”) in San Antonio, Texas." We are delighted to share new preclinical data on STX-478 that further demonstrates its potential best-in-class product profile and supports its advancement into first-in-human clinical trials," said Axel Hoos, M.D., Ph.D., Chief Executive Officer of Scorpion. " In these studies, STX-478 showed robust anti-tumor activity as both a monotherapy and in combination with standard of care agents in models with kinase or helical domain mutations. Importantly, this activity was coupled with key features that differentiate STX-478 from other PI3Kα inhibitors. STX-478 exhibited high mutant selectivity, without the dose-limiting metabolic dysfunction associated with currently available treatments

Scorpion Therapeutics Presents Preclinical Data For Potential Best-In-Class Pi3Kα Inhibitor At San Antonio Breast Cancer Symposium

BOSTON--(BUSINESS WIRE)--Scorpion Therapeutics, Inc. (“Scorpion”), a pioneering oncology company redefining the frontier of precision medicine through its Precision Oncology 2.0 strategy, today announced that it will present preclinical data on STX-478, its potential best-in-class mutant-selective PI3Kα inhibitor, in a poster session at San Antonio Breast Cancer Symposium (“SABCS”) in San Antonio, Texas, taking place December 6 – 10, 2022. STX-478 is a highly selective, allosteric and CNS-penetrant inhibitor of mutant PI3Kα, designed to improve outcomes in patients harboring tumors with prevalent PI3Kα kinase or helical domain mutations. Scorpion has completed IND-enabling studies for STX-478 and expects to submit an IND application to the U.S. Food and Drug Administration (“FDA”) in the first quarter of 2023

Scorpion Therapeutics To Present Preclinical Data For Potential Best-In-Class Mutant-Selective Pi3Kα Inhibitor At San Antonio Breast Cancer Symposium

BOSTON--(BUSINESS WIRE)--Scorpion Therapeutics, Inc. (“Scorpion Therapeutics”), a pioneering oncology company redefining the frontier of precision medicine through its Precision Oncology 2.0 strategy, today announced the formation of its Clinical Scientific Advisory Board (“Clinical SAB”). The Clinical SAB will complement the deep expertise of Scorpion Therapeutics’ leadership team, academic founders, Board of Directors, and the previously announced Discovery SAB to support the company in advancing its portfolio of potentially first- or best-in-class product candidates for the treatment of cancer. The members of Scorpion’s Clinical SAB include:

Scorpion Therapeutics Announces Formation Of World-Class Clinical Scientific Advisory Board

BOSTON--(BUSINESS WIRE)--Scorpion Therapeutics, Inc. (“Scorpion”), a pioneering oncology company redefining the frontier of precision medicine through its Precision Oncology 2.0 strategy, today announced preclinical proof-of-concept data for STX-721, the Company’s first development candidate from its STX-EGFR-EXON-20 program. STX-721 is a next-generation, orally delivered therapy, designed with potential best-in-class selectivity for exon 20 insertion mutations in epidermal growth factor receptors (“EGFR”), a well-known, clinically validated oncogenic driver in non-small cell lung cancer (“NSCLC”). The data will be presented today in a poster session at the European Organisation for Research and Treatment of Cancer, the National Cancer Institute, and the American Association for Cancer Research (“EORTC-NCI-AACR”) Symposium 2022 in Barcelona, Spain. “ We are excited to share the first preclinical data for STX-721, our next-generation, highly-differentiated EGFR exon 20 inhibitor,” said Axel Hoos, M.D., Ph.D., Chief Executive Officer of Scorpion. “ The discovery and progression of this development candidate in less than two years is further validation of our Precision Oncology 2.0 strategy, designed to exceed the speed, efficiency and quality of traditional target and drug discovery approaches. The data presented at EORTC-NCI-AACR support our selection of STX-721 as our second clinical program, demonstrating potentially best-in-class selectivity that we anticipate will result in a wider therapeutic index and greater efficacy compared to currently marketed therapies and other drug candidates in development. We look forward to submitting an IND application for STX-721 next year, as we aim to transform the lives of thousands of people living with exon 20 insertion mutant EGFR-driven NSCLC who are underserved by existing therapeutics.”

Scorpion Therapeutics Presents Preclinical Proof-Of-Concept Data For Stx-721, A Next-Generation Exon 20 Mutant Egfr Inhibitor, At The Eortc-Nci-Aacr Symposium 2022

Develops precision oncology treatments for cancer

Scorpion Therapeutics

Develops precision oncology treatments for cancer

Scorpion Therapeutics

Develops precision oncology treatments for cancer

About

Simplify's Take

What believers are saying

What critics are saying

What makes Scorpion Therapeutics unique

6 month growth

1 year growth

2 year growth

Recently Posted Jobs

Scorpion Therapeutics is Hiring for 0 Jobs on Simplify!